Papers
Effect of four monthly oral vitamin D (cholecalciferol)
3
supplementation on fractures and mortality in men and
women living in the community: randomised double blind
controlled trial
DakshaPTrivedi,RichardDoll,KayTeeKhaw
Abstract monthlysupplementationwithoralvitaminD onfrac› Clinical
tures and mortality in 2686 men and wom3 en aged GerontologyUnit,
ObjectiveTodeterminetheeffectoffourmonthly Universityof
65›85yearslivinginthecommunity. CambridgeSchool
vitaminDsupplementationontherateoffracturesin ofClinical
menandwomenaged65yearsandoverlivinginthe Medicine,
community. Methods Addenbrooke’s
Hospital,
DesignRandomiseddoubleblindcontrolledtrialof Studypopulation Cambridge
100000IUoralvitaminD (cholecalciferol) CB22QQ
3 This trial was a pilot to assess the feasibility of a
supplementationormatchingplaceboeveryfour DakshaPTrivedi
communitytrial(notsubsequentlyconductedowingto researchfellow
monthsoverfiveyears.
lack of funding) in 20000 men and women. We KayTeeKhaw
Settingandparticipants2686people(2037menand recruitedmenandwomenaged65›85fromtheBritish professorofclinical
649women)aged65›85yearslivinginthegeneral gerontology
doctors study register at the Clinical Trials Studies
community,recruitedfromtheBritishdoctorsregister Unit, Oxford,8 and the age›sex register of a general ClinicalTrial
andageneralpracticeregisterinSuffolk. ServiceUnitand
practice in Ipswich, Suffolk. Cambridge local ethics Epidemiological
MainoutcomemeasuresFractureincidenceandtotal committeeapprovedthestudy. StudiesUnit,
mortalitybycause. Universityof
ResultsAfterfiveyears268menandwomenhad Recruitmentandrandomisation Oxford
RichardDoll
incidentfractures,ofwhom147hadfracturesin Werecruitedparticipantsbyusingamailedletterand
emeritusprofessor
commonosteoporoticsites(hip,wristorforearm,or information sheet. We excluded people who were
Correspondenceto:
vertebrae).RelativerisksinthevitaminDgroup alreadytakingvitaminDsupplementsandpeoplewith KTKhaw
comparedwiththeplacebogroupwere0.78(95% conditions that were contraindications to vitamin D kk101@medschl.
confidenceinterval0.61to0.99,P=0.04)foranyfirst supplementation—for example, a history of renal cam.ac.uk
fractureand0.67(0.48to0.93,P=0.02)forfirsthip, stones,sarcoidosis,ormalignancy.
bmj.com2003;326:469
wristorforearm,orvertebralfracture.471 We sent invitations to 11120 people (9582 from
participantsdied.Therelativeriskfortotalmortality theBritishdoctorsstudyand1538fromgeneralprac›
inthevitaminDgroupcomparedwiththeplacebo tice), and 3504 (31.5%) of them (2907 from British
groupwas0.88(0.74to1.06,P=0.18).Findingswere doctorsstudyand597fromgeneralpractice)initially
consistentinmenandwomenandindoctorsandthe agreedtoparticipate.FromJune1996toMarch1997
generalpracticepopulation. werandomised2686(77.5%)peoplewhowereeligible
ConclusionFourmonthlysupplementationwith and gave informed consent,after stratification by age
100000IUoralvitaminDmaypreventfractures andsex,toreceiveeithertreatmentwithvitaminDora
withoutadverseeffectsinmenandwomenlivingin placebo.Participantsandinvestigatorswereblindedto
thegeneralcommunity. the treatment until the study ended, when Ipswich
Pharmacyrevealedthecoding.
Introduction Studydesign
We conducted the study by post. Participants
Osteoporoticfracturesareprojectedtoincreaseexpo›
completedaninitialquestionnaire.Weassessedpreva›
nentially worldwide.1 Most fracture prevention trials
lence of disease with the question “Do you have the
have focused on clinically defined groups such as
followingconditions?”followedbyachecklist.Weused
people with osteoporosis or previous fractures and
amodifiedfoodfrequencyquestionnaireatfouryears
have mainly been conducted in women.2–7 Safe,
toestimatedietarycalciumintake.
effective,feasible,andcosteffectiveprimaryprevention
measures are needed in older men and women, in Intervention
whom most osteoporotic fractures occur. We report Wesentonecapsulecontaining100000IUvitaminD
3
results from a randomised double blind trial of four (cholecalciferol) or matching placebo by post every
BMJ VOLUME326 1MARCH2003 bmj.com page1of6
Table1 Characteristicsof2037menand649womenaged65›85yearsatbaselinein1996,accordingtoallocationtotreatmentwith
vitaminDorplacebo.Valuesarenumbers(percentages)unlessstatedotherwise
All Men Women
VitaminD Placebo VitaminD Placebo VitaminD Placebo
Baselinevariables (n=1345) (n=1341) (n=1019) (n=1018) (n=326) (n=323)
Mean(SD)ageatrandomisation(years) 74.8(4.6) 74.7(4.6) 75.2(4.6) 75.0(4.6) 73.7(4.5) 73.6(4.6)
Mean(SD)bodymassindex(kg/m2) 24.3(3.4) 24.4(3.0) 24.3(3.3) 24.4(2.7) 24.4(3.8) 24.3(3.8)
Historyofheartdisease* 223(16.6) 208(15.5) 189(18.5) 181(17.8) 34(10.4) 27(8.4)
Historyofstroke 51(3.8) 57(4.3) 42(4.1) 48(4.7) 9(2.8) 9(2.8)
Historyofcardiovasculardisease† 394(29.3) 367(27.4) 329(32.3) 312(30.6) 65(19.9) 55(17.0)
Historyofcancer‡ 82(6.1) 79(5.9) 67(6.6) 69(6.8) 15(4.6) 10(3.1)
Currentsmokers 59(4.4) 53(4.0) 39(3.8) 29(2.8) 20(6.1) 24(7.4)
Currentuseofsteroids 60(4.5) 70(5.2) 42(4.1) 53(5.2) 18(5.5) 17(5.3)
Currentuseofhormonereplacementtherapy NA NA NA NA 21(6.4) 21(6.5)
Alcoholintake§: (n=1295) (n=1279) (n=972) (n=968) (n=323) (n=311)
Never 132(10.2) 115(9.0) 77(7.9) 64(6.6) 55(17.0) 51(16.4)
Occasional 197(15.2) 205(16.0) 102(10.5) 115(11.9) 95(29.4) 90(28.9)
Regular 966(74.6) 959(75.0) 793(81.6) 789(81.5) 173(53.6) 170(54.7)
Physicalactivity§: (n=1288) (n=1276) (n=969) (n=963) (n=319) (n=313)
Activeormoderatelyactive 1119(86.9) 1133(88.8) 840(86.7) 852(88.5) 279(87.5) 281(89.8)
NA=notapplicable.
*Selfreportedangina,myocardialinfarction,orischaemicheartdisease.
†Ischaemicheartdisease,stroke,orothercardiovasculardisease.
‡Includesselfreportedskincancers(includingmelanoma),whichcompriseabout80%ofprevalentcancer;peoplereportingcancerafterrandomisationbutbefore
takingthefirstcapsulearereportedasprevalentcancer.
§Excludesmissingdata.
fourmonthsforfiveyears(15dosesintotal).Weasked Statisticalanalyses
participants to take the capsule immediately on Weincludedallparticipantsrandomisedtoactivevita›
receipt,completeaformindicatingthattheyhaddone min D or placebo in the analyses, according to
so,andreturntheformbyFreepost. intention to treat. We compared relative risks for
Thedosehadpreviouslybeenshowntobesafe,to incidenceoffracture,mortalitybycause,andincidence
raise blood 25›hydroxyvitamin D concentrations to ofcardiovasculardiseaseandcancerforactivevitamin
physiologicallevelsachievablebylifestylemeans,and Dversusplacebobyusingcruderatesandthen,after
to have a measurable impact on concentrations of adjustmentforage,withtheCoxregressionmethod,12
parathyroid hormone over several weeks.9 The byusingSPSSsoftware,version10.0.
expected differences in blood concentrations of
25›hydroxyvitamin D and parathyroid hormone are
Results
associatedwithdifferencesinbonedensityandfracture
risk.1011 Characteristicsofparticipants
Participants continued any usual drug treatment Table1showsbaselinedescriptivedata.Meancalcium
and any new drugs that were advised during routine intakeatfouryearswas742mg/dayanddidnotdiffer
care. If they were advised to start vitamin D bytreatmentallocation.
supplementsofmorethan200IUdailytheydiscontin›
uedthetrialinterventionbutcontinuedtobefollowed Incidenceoffracture
forendpoints. Table 2 shows five year fracture rates. Participants in
thevitaminDtreatmentgrouphada22%lowerrate
Endpointascertainment forfirstfractureatanysiteanda33%lowerratefora
Onreceivingthecapsule,participantsfilledinacheck› fracture occurring in the hip, wrist or forearm, or
list of events (fracture or major illness) and returned
theformbyFreepost.Allparticipantswereflaggedat
the Office for National Statistics for mortality and 0.14
followeduntil31March2002.Anosologistblindtothe
intervention coded death certificates by using ICD›9 0.12
(international classification of diseases, 9th revision). 0.10
We ascertained incidences of fracture, cardiovascular
0.08
disease, and cancer by using events identified from
questionnairesordeathcertificationbycause. 0.06
Serum25›hydroxyvitaminD,parathyroidhormone, 0.04
andheelsonometry 0.02
Afterfouryearsweinvited235participantsfromgen›
eral practice who had taken at least 10 capsules to a
clinic for measurement of serum vitamin D and
Months
parathyroid hormone concentrations. The visit took
place in September and October, about three weeks
after a dose. We assessed heel bone sonometry with
CUBAequipment(McCueUltrasonics,Winchester).
erutcarf
fo
ytilibaborp
evitalumuC
Papers
Vitamin D
Placebo
0
0 10 20 30 40 50 60 70
Fig1 Cumulativeprobabilityofanyfirstfractureaccordingto
treatmentwithvitaminD(n=1345)orplacebo(n=1341),basedon
Coxregression;differencebetweentwogroups,P=0.04
page2of6 BMJ VOLUME326 1MARCH2003 bmj.com
Table2 Incidenceoffracturesbasedonselfreportormortalitycertification1996›2002
andageadjustedrelativerisks(Coxregression),accordingtotreatmentallocationat
randomisation(intentiontotreat)in2686menandwomenaged65›85years.Values
arenumbers(percentages)unlessstatedotherwise
Ageadjustedrelative
Fractures VitaminD Placebo risk(95%CI) Pvalue*
All (n=1345) (n=1341)
Anysite 119(8.8) 149(11.1) 0.78(0.61to0.99) 0.04
Hip,wristorforearm,orvertebrae 60(4.5) 87(6.5) 0.67(0.48to0.93) 0.02
Hiporwristorforearm 43(3.2) 62(4.6) 0.67(0.46to0.99) 0.04
Hip 21(1.6) 24(1.8) 0.85(0.47to1.53) 0.59
Vertebrae 18(1.3) 28(2.1) 0.63(0.35to1.14) 0.12
Men (n=1019) (n=1018)
Months Anysite 77(7.6) 91(8.9) 0.83(0.61to1.13) 0.24
Hip,wristorforearm,orvertebrae 36(3.5) 50(4.9) 0.70(0.46to1.08) 0.11
Hiporwristorforearm 22(2.2) 31(3.0) 0.70(0.40to1.20) 0.19
Hip 11(1.1) 14(1.4) 0.76(0.35to1.67) 0.49
Vertebrae 14(1.4) 22(2.2) 0.62(0.32to1.22) 0.17
Women (n=326) (n=323)
vertebrae.Thedifferenceswereconsistentwhenstrati› Anysite 42(12.9) 58(18.0) 0.68(0.46to1.01) 0.05
Hip,wristorforearm,orvertebrae 24(7.4) 37(11.5) 0.61(0.37to1.02) 0.06
fiedbysexorbydoctorversusgeneralpracticepopu›
Hiporwristorforearm 21(6.4) 31(96) 0.64(0.37to1.11) 0.11
lation.Weobserveddifferencesoneyearintothestudy
Hip 10(3.1) 10(3.1) 0.98(0.41to2.36) 0.97
(fig1).
Vertebrae 4(1.2) 6(1.9) 0.65(0.18to2.30) 0.50
Otherhealthevents *Pvalue(twosided)referstodifferencebetweentreatmentgroups.
Table 3 shows cumulative mortality to March 2002.
ThevitaminDgrouphadslightlybutnotsignificantly fracturethroughselfreportbyquestionnaire.Thismay
lowermortalityfromallcauses,cardiovasculardisease, have led to ascertainment errors, but random errors
andcancerthantheplacebogroup.Figure2showsthe wouldunderestimateassociations.Inthisrandomised
cumulative probability of survival in the vitamin D double blinded design,biased ascertainment between
group compared with the placebo group over five the treatment groups is unlikely. Most of the
years. Table 4 shows the incidence of major health participants were doctors, which increases the likeli›
events. These did not differ significantly between the
treatmentgroups.
Table3 Mortalityfromallcauses,cardiovasculardisease,andcancerbydeath
Physiologicalvariablesandcompliance certification1996›2002andageadjustedrelativerisks(Coxregression),accordingto
Table5showsmeanserumconcentrationsofvitamin treatmentallocationatrandomisation(intentiontotreat)in2686menandwomenaged
65›85years.Valuesarenumbers(percentages)unlessstatedotherwise
Dandparathyroidhormoneandheelboneultrasound
attenuationinthesubgroup.MeanvitaminDconcen› Ageadjustedrelative
trationswere40%higherintheactivetreatmentgroup Causeofdeath* VitaminD Placebo risk(95%CI) Pvalue†
All (n=1345) (n=1341)
than in the placebo group. Mean parathyroid
Allcauses 224(16.7) 247(18.4) 0.88(0.74to1.06) 0.18
concentrationswere6%lower,butthisdifferencewas
Cardiovasculardisease 101(7.5) 117(8.7) 0.84(0.65to1.10) 0.20
notsignificant.Heelultrasoundmeasuresdidnotdiffer
Ischaemicheartdisease 42(3.1) 49(3.7) 0.84(0.56to1.27) 0.41
bytreatment.
Cerebrovasculardisease 28(2.1) 26(1.9) 1.04(0.61to1.77) 0.89
Compliancedidnotdifferbetweendoctorsandthe
Cancer 63(4.7) 72(5.4) 0.86(0.61to1.20) 0.37
generalpracticepopulationorbetweenthetreatment Colon 7(0.5) 11(0.8) 0.62(0.24to1.60) 0.33
groups;76%(2050/2686)ofparticipantshadatleast Respiratory 10(0.7) 11(0.8) 0.89(0.38to2.09) 0.78
80% compliance (12/15 doses). Compliance for the Men (n=1019) (n=1018)
final dose was 66% (1784/2686); excluding partici› Allcauses 199(19.5) 220(21.2) 0.88(0.73to1.07) 0.19
pants who had died, we estimated compliance to be Cardiovasculardisease 90(8.8) 106(10.4) 0.83(0.62to1.10) 0.19
80%(1784/2215).Atotalof631(23.5%)participants, Ischaemicheartdisease 38(3.7) 45(4.4) 0.83(0.54to1.28) 0.40
includingthosewhodied,didnotcompletethefullfive Cerebrovasculardisease 24(2.4) 25(2.5) 0.92(0.52to1.61) 0.77
years to March 2002—22.8% (307) in the vitamin D Cancer 56(5.5) 59(5.8) 0.93(0.64to1.34) 0.69
groupand24.2%(324)intheplacebogroup(P=0.41). Colon 7(0.7) 7(0.7) 0.97(0.34to2.78) 0.96
Respiratory 10(1.0) 9(0.9) 1.08(0.44to2.65) 0.87
No significant difference existed between the two
Women (n=326) (n=323)
groupsinthenumberknowntobealivebutwhowith›
Allcauses 25(7.7) 27(8.4) 0.91(0.53to1.56) 0.73
drew (that is, discontinued questionnaire follow up)
Cardiovasculardisease 11(3.4) 11(3.4) 0.99(0.43to2.30) 0.99
from the study: 5.7% (77) in the placebo group and
Ischaemicheartdisease 4(1.2) 4(1.2) 0.99(0.25to3.96) 0.99
6.2%(83)intheactivegroup(P=0.64).
Cerebrovasculardisease 4(1.2) 1(0.3) 3.98(0.44to35.64) 0.22
Cancer 7(2.1) 13(4.0) 0.53(0.21to1.33) 0.18
Discussion Colon 0 4(1.2) NA 0.04
Respiratory 0 2(0.6) NA 0.16
Among men and women aged 65›85 living in the Breast 0 0 NA NA
general population, those allocated to supplementa› NA=notapplicable.
tionwithvitaminDhadlowerratesoffractureatany
*Cardiovasculardisease=ICD›9codes390.0›459.9;ischaemicheartdisease=410.0›414.0;cerebrovascular
disease=430.0›438.0;cancer=140.0›239.9;coloncancer=153.0›154.8;respiratorycancer=160.0›165.9;
siteoratanymajorosteoporoticsite(hip,wristorfore› breastcancer=174.0›175.0;eachasunderlyingcause.
arm, or vertebrae). We ascertained the incidence of †Pvaluereferstodifferencebetweentreatmentgroups.
lavivrus
fo
ytilibaborP
Papers
1.0
Vitamin D
Placebo
0.9
0.8
0.7
0 10 20 30 40 50 60 70
Fig2 CumulativesurvivalaccordingtotreatmentwithvitaminD
(n=1345)orplacebo(n=1341),basedonCoxregression;no
significantdifferencebetweengroups
BMJ VOLUME326 1MARCH2003 bmj.com page3of6
Papers
Comparisonswithpreviousstudies
Table4 Incidenceofcardiovasculardisease,cancer,andotherhealthevents1996›2002
Severalstudiesreportthatdailysupplementationwith
andageadjustedrelativerisks,accordingtotreatmentallocationatrandomisation
(intentiontotreat)in2686menandwomenaged65›85years.Valuesarenumbers vitamin D and calcium reduces fractures.23 Chapuy
(percentages)unlessstatedotherwise reported that daily supplementation with vitamin D
800IUandcalciumreducedhipfracturesby30%over
Ageadjustedrelative
Healthevent VitaminD Placebo risk(95%CI) Pvalue* threeyearsin3270elderlywomen.2Whethercalcium
All (n=1345) (n=1341) alone, vitamin D alone, or the combination was
Cardiovasculardisease† 477(35.5) 503(37.5) 0.90(0.77to1.06) 0.22 responsible for these effects is not clear.In our study
Ischaemicheartdisease 224(16.7) 233(17.4) 0.94(0.77to1.15) 0.57 theeffectsizeofisolatedvitaminDsupplementation—
Cerebrovasculardisease 105(7.8) 101(7.5) 1.02(0.77to1.36) 0.87
about20%reductionintotalfracturesand30%reduc›
Cancer†(any) 188(14.0) 173(12.9) 1.09(0.86to1.36) 0.47
tion in fractures at major osteoporotic sites—is
Cancer†(excludingskin) 144(10.8) 130(9.6) 1.11(0.86to1.42) 0.43
comparabletothatreportedbyChapuyforcombined
Coloncancer 28(2.1) 27(2.0) 1.02(0.60to1.74) 0.94
Respiratorycancer 17(1.3) 15(1.1) 1.12(0.56to2.25) 0.75 dailyvitaminDandcalcium.2
Selfreportedfalls‡ (n=1027) (n=1011) PreviousstudiesofisolatedvitaminDsupplemen›
254(24.7) 261(25.8) 0.93(0.76to1.14) 0.50 tation have been inconclusive.15–17 The lack of
Selfreportedhealth‡: (n=1017) (n=1002) significantreductioninfracturesinthesestudiescould
Excellentorgood 788(77.5) 760(75.8) 1.13(0.91to1.39) 0.27 beexplainedbyalackofpowerduetoalowerdoseof
Men (n=1019) (n=1018)
supplement, shorter duration, or lower number of
Cardiovasculardisease† 392(38.5) 412(40.5) 0.91(0.76to1.09) 0.30
events as well as ineffectiveness of vitamin D. Lips
Ischaemicheartdisease 191(18.7) 193(19.0) 0.98(0.78to1.22) 0.86
foundnoprotectiveeffectofvitaminD400IUdailyin
Cerebrovasculardisease 86(8.4) 85(8.3) 0.99(0.72to1.36) 0.96
Cancer†(any) 163(16.0) 147(14.4) 1.11(0.87to1.42) 0.39
1578participants.16Thisdosemayhavebeentoolow
Cancer†(excludingskin) 129(12.7) 111(10.9) 1.17(0.89to1.54) 0.26 to achieve a clinical effect. In our study the four
Coloncancer 25(2.5) 21(2.1) 1.18(0.65to2.12) 0.59 monthly 100000 IU dose averages a daily equivalent
Respiratorycancer 17(1.7) 13(1.3) 1.29(0.62to2.68) 0.49 similar to the 800 IU vitamin D used in the trials by
Selfreportedfalls‡ (n=757) (n=756) Chapuy and Dawson Hughes.23 Heikinheimo, using
154(20.3) 169(22.4) 0.87(0.68to1.12) 0.27
annual injections of 150000›300000 IU in 899
Selfreportedhealth‡: (n=749) (n=750)
participants, reported a reduction in fractures of the
Excellentorgood 577(77.0) 582(77.6) 1.00(0.78to1.28) 0.99
Women (n=326) (n=323)
upperlimbbutnotthelowerlimb.17Thisstudywasnot
Cardiovasculardisease† 85(26.1) 91(28.2) 0.89(0.63to1.27) 0.52 properly randomised or blinded,and a single annual
Ischaemicheartdisease 33(10.1) 40(12.4) 0.79(0.48to1.29) 0.35 dosemaynotprovideadequateconcentrationsinthe
Cerebrovasculardisease 19(5.8) 16(5.0) 1.19(0.60to2.37) 0.62 bloodoverawholeyear.
Cancer†(any) 25(7.2) 26(8.0) 0.95(0.54to1.68) 0.85 Vitamin D may protect against fractures through
Cancer†(excludingskin) 15(4.6) 19(5.9) 0.77(0.39to1.55) 0.47 concentrationsofparathyroidhormone.Lowconcen›
Coloncancer 3(0.9) 6(1.9) 0.49(0.12to1.98) 0.32
trations of vitamin D are associated with increased
Respiratorycancer 0 2(0.6) NA 0.16
concentrations of parathyroid hormone, increased
Breastcancer 4(1.2) 4(1.2) 0.99(0.25to3.99) 0.99
Selfreportedfalls‡ (n=270) (n=255) bone resorption, and lower bone mass.9–11 The 40%
highermeanconcentrationsofvitaminDseeninthe
100(37.0) 92(36.1) 1.03(0.72to1.48) 0.86
Selfreportedhealth‡: (n=268) (n=252) activetreatmentgroupinourtrialwerestillnothigh
Excellentorgood 211(78.7) 178(70.6) 1.57(1.05to2.35) 0.03 in absolute terms. Parathyroid hormone concentra›
NA=notapplicable. tions were only slightly and not significantly lower.
*Pvaluereferstodifferencebetweentreatmentgroups. Thissuggeststhat100000IUvitaminDfourmonthly
†Selfreportedincidenceorwhenindicatedascauseofdeathanywhereondeathcertificatefrommortality
certification;ICDcodingasintable3. maynothaveloweredparathyroidhormoneconcen›
‡Datacollectedatendoftrial;excludesmissingdata.Selfreportedfallsareapositiveresponsetothe trations adequately,and a more frequent dose might
question,“Haveyouhadanyfallsinthepast12months?”
beconsideredinfuturetrials.
We found no significant effects of vitamin D on
hood of accurate ascertainment of events. Fracture total mortality or incidence of cancer or cardiovas›
rates did not differ significantly between doctors and culardisease,assuggestedbyobservationalstudies.1819
thegeneralpracticepopulation,indicatingthatpeople However, the fact that the relative risks were in a
in the general community report fracture accurately, favourable direction in the active treatment group is
anassumptionsupportedbyseveralstudies.1314 reassuring.
Table5 Boneheelultrasoundattenuation,velocityofsound,andconcentrationsofserumvitaminDandparathyroidhormoneinsubgroupofparticipants
fromgeneralpractice.Valuesaremeans(standarddeviations)unlessstatedotherwise
All Men Women
VitaminD Placebo VitaminD Placebo VitaminD Placebo
Measurement (n=124) (n=114) Pvalue (n=65) (n=57) Pvalue (n=59) (n=57) Pvalue
Age(years) 76.1(5.1) 75.4(4.1) 0.20 75.7(5.1) 75.0(3.6) 0.37 76.6(5.1) 75.7(4.5) 0.33
Bodymassindex(kg/m2) 27.4(4.2) 26.6(4.2) 0.15 26.9(4.0) 26.2(3.0) 0.30 28.0(4.5) 27.1(5.1) 0.28
VitaminD(nmol/l) 74.3(20.7) 53.4(21.1) <0.001 75.6(19.0) 61.0(21.5) <0.001 72.0(22.5) 45.37(17.6) <0.001
Parathyroidhormone(pmol/l) 5.2(2.0) 5.5(2.4) 0.25 4.8(2.0) 5.0(2.0) 0.68 5.6(1.9) 6.13(2.6) 0.25
Boneheelultrasoundattenuation 74.4(21.9) 72.3(19.7) 0.45 89.1(15.4) 83.5(16.2) 0.05 57.9(15.4) 60.95(16.3) 0.30
(dB/MHz)
Velocityofsound(m/s) 1618.1(41.2) 1613.6(38.6) 0.39 1641.1(32.2) 1629.2(34.5) 0.05 1592.4(34.5) 1597.7(36.2) 0.42
page4of6 BMJ VOLUME326 1MARCH2003 bmj.com
Papers
Generalisability
What is already known in this topic
Tomaximisegeneralisability,thiswasapragmatictrial
withminimalexclusioncriteria.Thedoctorsweresimi› VitaminDandcalciumsupplementsareeffective
lartothegeneralpracticepopulationintermsofcom› inpreventingfracturesinelderlywomen
pliance,fracturerates,andeffectsofvitaminD.Blood
concentrationsofvitaminDinparticipantstakingpla› WhetherisolatedvitaminDsupplementation
cebowerecomparabletothoseofpopulationgroups preventsfracturesisnotclear
of similar ages in northern latitudes in the United What this paper adds
States3andhigherthanthoseinolderEuropeanpopu›
lations living in northern latitudes.1620 If vitamin D Fourmonthlyoralsupplementationwith
supplementation is safe and effective for fracture 100000IUvitaminDreducesfracturesinmen
prevention, even in relatively replete healthy partici› andwomenagedover65livinginthegeneral
pants,itisunlikelytobeoflesserbenefitinpeoplewith community
lowervitaminDlevels.
Totalfractureincidencewasreducedby22%and
fracturesinmajorosteoporoticsitesby33%
Publichealthimplications
This trial was a pilot for a larger trial that was not
funded and was, consequently, too small for any
decisiveeffectonfracturestobeexpected.Theresults,
Conclusion
nevertheless, indicate that isolated vitamin D supple› Wefoundasingleoral100000IUdoseofvitaminD
mentation prevents fractures. This is particularly four monthly to be acceptable, safe, and effective in
important for primary prevention. Several reducingtheincidenceoffractureinmenandwomen
interventions—such as bisphosphonates, oestrogen, agedover65livinginthegeneralcommunity.
and calcium and vitamin D—reduce fractures in high
riskgroups.2–7Theirapplicationtoprimaryprevention WethankalltheparticipantsinthetrialfromtheBritishdoctors
studyandthegeneralpracticeinIpswich.WealsothankAJ
is,however,problematicasthebalanceofrisk›benefit
HicksandcolleaguesattheNorwichRoadSurgery,Ipswich;G
andcost›benefitdiffersinprimaryandsecondarypre› Hanson,IpswichHospitalNHSTrustPharmacyManufacturing
vention. Department;RichardDexter,PelicanComputing,forcomput›
The alendronate trial identified 2000 women at ingsupport;RosemaryReaderandSandraOwenfordatabase
assistance;and Sir Richard Peto for advice and access to the
high risk of fracture (low bone mineral density and
British doctors. The 100000 IU vitamin D supplement or
previous fracture).4 The 25% reduction in fractures placebousedinthistrialwasspeciallypreparedbytheIpswich
seen translates to an absolute benefit of 60 women Hospital Pharmacy. Ergocalciferol (physiologically the same
actionascholecalciferol)50000IUisobtainablefromchemists.
treated for one year to prevent any fracture; the
Contributors:KTKandDPToriginatedanddesignedthetrial,
absolute benefit was lower in a later trial on women
withhelpfromRD.DPTcoordinatedthestudyandmanagedall
without a previous fracture.5 Whereas relative reduc› aspectsofthetrial,includingconductandinitiallyblindeddata
tions in fracture may be generalisable, the absolute analyses,whichwereplannedandcheckedwithKTKandRD.
benefit differs in groups in which absolute fracture DPTwrotethepaperwithKTKandRD.KTKisguarantorfor
thispaper.
risksarelower.The22%reductioninfracturesinour
Funding:StartupgrantfromtheMedicalResearchCouncil.
study translates to approximately 250 people treated
Competinginterests:Nonedeclared.
foroneyeartopreventanyfracture.
Riskoffractureisrelatedtobonehealthacrossthe
1 CooperC,CampionG,MeltonLJ3rd.Hipfracturesintheelderly:a
wholepopulationdistribution,suchthatmostfractures
world›wideprojection.OsteoporosInt1992;2:285›9.
do not occur in the small numbers of people with 2 ChapuyMC,ArlotME,DuboeufF,BrunJ,CrouzetB,ArnaudS,etal.
VitaminD3andcalciumtopreventhipfracturesintheelderlywomen.N
severe osteoporosis at very high risk but in the large
EnglJMed1992;327:1637›42.
numbers at moderately increased risk. To have a 3 Dawson›HughesB,HarrisSS,KrallEA,DallalGE.Effectofcalciumand
vitaminDsupplementationonbonedensityinmenandwomen65years
substantial effect on total fractures in the population,
ofageorolder.NEnglJMed1997;337:670›6.
intervention would be needed in large numbers of 4 BlackDM,CummingsSR,KarpfDB,CauleyJA,ThompsonDE,Nevitt
MC,etal.Randomisedtrialofeffectofalendronateonriskoffracturein
people; consequently, population›wide preventive
womenwithexistingvertebralfractures.Lancet1996;348:1535›41.
interventions have been proposed for all elderly 5 Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett›
ConnorE,MuslinerTA,etal.Effectofalendronateonriskoffracturein
people.21
womenwithlowbonedensitybutwithoutvertebralfractures:results
However, the dilemma for primary prevention is fromthefractureinterventiontrial.JAMA1998;280:2077›82.
6 McClungMR,GeusensP,MillerPD,ZippelH,BensenWG,etal.Effectof
that whereas the population attributable risk is large, risedronateontheriskofhipfractureinelderlywomen.NEnglJMed
theabsoluteindividualriskisstilllow.22Therisk›benefit 2001;344:333›40.
7 WritingGroupfortheWomen’sHealthInitiative.Risksandbenefitsof
balanceforcommunitybasedpreventiondiffersfrom estrogen plus progestin in healthy postmenopausal women. JAMA
that for intervention in clinically defined groups. 2002:288:321›33.
8 DollR,PetoR,HallE,WheatleyK,GrayR.Mortalityinrelationtocon›
Safety,feasibility,andcosteffectivenessarecrucial.Side sumptionofalcohol:13years’observationsonmaleBritishdoctors.BMJ
effectsarelessacceptableinahealthygroupinwhich 1994;309:911›8.
9 KhawKT,ScraggR,MurphyS.Singledosecholecalciferol(vitaminD3)
theriskoffractureisnothigh.Thisisaparticularissue suppressesthewinterincreaseinparathyroidhormoneconcentrationsin
inmen,inwhomevidenceoneffectivefracturepreven› normaloldermenandwomen:arandomizedtrial.AmJClinNutr
1994;59:1040›4.
tionislacking.Manyinterventionseffectiveinhighrisk 10 ParfittAM,GallagherJC,HeaneyRP,JohnstonCC,NeerR,WhedonGD.
groups are not feasible in the general population VitaminDandbonehealthintheelderly.AmJClinNutr1982;36:1014›31.
11 KhawKT,SneydMJ,CompstonJ.Bonedensityparathyroidhormone
owing to poor compliance or side effects or are not and25›hydroxyvitaminDconcentrationsinmiddleagedwomen.BMJ
cost effective.23 In contrast, the cost of four monthly 1992;305:273›7.
12 Cox DR. Regression models and life tables. J R Stat Soc B
oral100000IUvitaminDisminimal(<£1annually). 1972;34:187›220.
BMJ VOLUME326 1MARCH2003 bmj.com page5of6
Papers
13 IsmailAA,O’NeillTW,CockerillW,FinnJD,CannataJB,HoszowskiK,et 19 GarlandCF,GarlandFC,GorhamED.CalciumandvitaminD:their
al.Validityofself›reportoffractures:resultsfromaprospectivestudyin potentialrolesincolonandbreastcancerprevention.AnnNYAcadSci
menandwomenacrossEurope.OsteoporosInt2000;11:248›54. 1999;889:107›19.
14 NevittMC,CummingsSR,BrownerWS,SeeleyDG,CauleyJA,VogtTM, 20 ChapuyMC,PreziosiP,MaamerM,ArnaudS,GalanP,HercbergS,etal.
etal.Theaccuracyofself›reportoffracturesinelderlywomen:evidence PrevalenceofvitaminDinsufficiencyinanadultnormalpopulation.
fromaprospectivestudy.AmJEpidemiol1992;135:490›9. OsteoporosInt1997;7:439›43.
15 GillespieWJ,HenryDA,O’ConnellDL,RobertsonJ.VitaminDandvita› 21 Barrett›ConnorE,GoreR,BrownerWS,CummingsSR.Preventionof
minDanaloguesforpreventingfracturesassociatedwithinvolutional osteoporotichipfracture:globalversushigh›riskstrategies.OsteoporosInt
and post›menopausal osteoporosis. Cochrane Database Syst Rev
1998;8:S2›7.
2002;(3):CD000227.
22 RoseG.Strategyofpreventivemedicine.Oxford:OxfordUniversityPress,
16 LipsP,GraafmansWC,OomsME,BezemerPD,BouterLM.VitaminD
supplementation and fracture incidence in elderly persons. A 1992.
randomized, placebo›controlled clinical trial. Ann Intern Med 23 Torgerson D, Donaldson C, Reid D. Using economics to prioritize
1996;124:400›6. research:acasestudyofrandomizedtrialsforthepreventionofhipfrac›
17 Heikinheimo RJ,Inkovaara JA,Harju EJ,Haavisto MV,Kaarela RH, turesduetoosteoporosis.JHealthServResPolicy1996;1:141›6.
KatajaJM,etal.AnnualinjectionofvitaminDandfracturesofaged
bones.CalcifTissueInt1992;51:105›10.
18 ScraggR,JacksonR,HoldawayIM,LimT,BeagleholeR.Myocardialinf›
arctionisinverselyassociatedwithplasma25›hydroxyvitaminD3levels:
acommunitybasedstudy.IntJEpidemiol1990:19:559›62. (Accepted10December2002)
page6of6 BMJ VOLUME326 1MARCH2003 bmj.com
